Next 10 |
home / stock / vrtx / vrtx articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrade...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 12.7% on an annualized basis producing an average annual...
On CNBC's “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management named NVIDIA Corporation (NASDAQ:NVDA) a...
Friday, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with c...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.91% on an annualized basis producing an average annual ...
On Tuesday, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced that it will present Phase 1 results in healthy volunteers and new Pha...
The Nasdaq 100 closed slightly lower on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it coul...
Joseph M. Terranova of Virtus Investment Partners named VanEck Semiconductor ETF (NASDAQ:SMH) on CNBC's “Halftime Report Final Trades....
On CNBC's “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. (NYSE:PFE) is a g...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...